ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 500 iu / 4 ml - coagulation factor viii

ישראל - עברית - Ministry of Health

alexion pharma israel ltd - sebelipase alfa - תרכיז להכנת תמיסה לאינפוזיה - sebelipase alfa 2 mg / 1 ml - sebelipase alfa

ישראל - עברית - Ministry of Health

megapharm ltd - anethole; borneol; camphene; cineole; fenchone; pinene alfa; pinene beta - קפסולות - camphene 15 mg; cineole 3 mg; fenchone 4 mg; borneol 10 mg; anethole 4 mg; pinene beta 6.2 mg; pinene alfa 24.8 mg

ישראל - עברית - Ministry of Health

medison pharma ltd - cerliponase alfa - תמיסה לאינפוזיה - cerliponase alfa 30 mg / 1 ml - cerliponase alfa

ישראל - עברית - Ministry of Health

kamada ltd, israel - velmanase alfa - אבקה להכנת תמיסה לאינפוזיה - velmanase alfa 10 mg/vial - velmanase alfa

ישראל - עברית - Ministry of Health

alexion pharma israel ltd - andexanet alfa - אבקה להכנת תמיסה לאינפוזיה - andexanet alfa 200 mg/vial - andexanet alfa

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - turoctocog alfa pegol - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa pegol 1000 iu/vial

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 3 miu / 0.5 ml - solution for injection - interferon alfa-2a - condylumata acuminata. hepatitis b,c. hairy cell leukemia. cml. aids related kaposis sarcoma. renal cell carcinoma.follicular non-hodgkin's lymphoma. patients with ajcc stage ii malignant melanoma (breslow tumour thickness > 1.5 mm, no lymph node involvement or cutaneous spread) who are free of disease after surgery.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 4.5 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 6 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m